Pharma Integrates 2023 Track 2

Big Health Issues and Enablers

How do we tackle some of the biggest health challenges, such as chronic conditions, respiratory and cancer?

How do we enable a better Industry, through creating diverse skilled teams, empowering the patient and navigating the economic and regulatory environment?

Welcome and Fireside Chat

Welcome & Opening Remarks

Susan Rienow | Country President UK, Pfizer | President, ABPI

Introduced by:

Trevor Jones CBE | Chairman, e-Therapeutics | Board Member, Respiratory Innovation Wales and Ascension Healthcare

Fireside Chat

Pharma CEO Plenary Discussion: View from the top – navigating the opportunities and challenges presented by a dynamic UK environment and achieving success.

Speakers include:

Susan Rienow | Country President UK, Pfizer | President, ABPI

Marie-Andrée Gamache | Country President | Novartis UK and Ireland

Dr Antonio Payano | Chief Executive Officer | Bayer UK & Ireland

Interviewed by:

Tamsin Berry | Head of Policy and Partnerships, AreteiaTx | Partner, Population Health Partners

Session 1: Panel Discussion followed by Q&A

Have a little ‘patients’

The patient voice is getting louder in all aspects of healthcare, from self-diagnosis to policy discussion and clinical trial design. What more can be done to engage patient groups and put patients at the centre of their healthcare journey?


Kathryn Simpson | Business Consultant | Kathryn Simpson Consulting Limited


Charlotte Harris | Head of Front End Innovation | Team Consulting

Oleksandr Gorbenko | Global Patient Affairs Director | Ipsen

Catherine Kettleborough | Translational Challenge Leader | LifeArc

Abigail Epstein | Head of Communications and Patient Advocacy | Takeda

Session 2: Panel Discussion followed by Q&A

Britain’s got talent?

As our ability to treat diseases becomes ever more advanced, the skills gap across the pharmaceutical sector continues to grow. How can we upskill our workforce, better manage talent, and encourage diversity to drive innovation?


Jane Kennedy | Chief Business Officer | Discovery Park


Fiona Marston | Chair & Chief Executive Officer | Erebagen

Nick Smith | Regional Operations Manager | Scitech

Amina Udechuku | Head of Vaccines, UK | Takeda UK

Andrew Croydon | Director, Education and Examination Policy & Partnerships | The ABPI

Session 3: Panel Discussion followed by Q&A


From ‘sick care’ to ‘health care’

With NHS demand outstripping capacity, we must focus on preventative healthcare. How can we turn a ‘sick care’ service into a ‘health care’ service that supports a healthier and wealthier nation?


John Deanfield CBE | Professor of Cardiology | University College London


Marcel Gehrung | Chief Executive Officer and Co-Founder | Cyted

Cedi Frederick | Chair | NHS Kent and Medway

Tamsin Berry | Partner & Head of Policy and Partnerships | AreteiaTx & Population Health Partners

Sir Keith Mills GBE DL | Chairman | Camelot

Session 4: Panel Discussion followed by Q&A


Trialling a new approach to clinical trials

Adaptive trials, decentralised trials, virtual trials … many new clinical trials models are appearing on the scene. How can the UK deliver more innovative trials across the board to make the most of assets within the NHS?


Lord James O’Shaughnessy | Senior Partner | Newmarket Strategy


James Chennells | Head Exploration & Discovery R&D Data Science & Artificial Intelligence | Bayer

Paul Wicks | Independent Consultant | Wicks Digital Health

Miranda Mapleton | Chief Executive Officer | White Swan

Nina Skorytchenko | Co-founder & Chief Executive Officer | Avenna

Session 5: Panel Discussion followed by Q&A


But does it sell?

Regulatory and commercialisation strategies can make or break the success of new treatments. How can we streamline processes to accelerate market access and deliver ‘value’?


Martino Picardo | Chairman | Discovery Park


Suzanne Dilly | Chief Executive Officer | ValiRx PLC

Camilla Easter | Chief Executive Officer | Oxford Medical Products

Hilary Mills-Baker | European Quality and Validation Manager | Emerson

Andrew Webb | Chief Executive Officer | Extruded Pharmaceuticals